Cover
Cover - shares | 9 Months Ended | |
Dec. 31, 2021 | Feb. 02, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Document Period End Date | Dec. 31, 2021 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2021 | |
Current Fiscal Year End Date | --03-31 | |
Entity File Number | 000-53230 | |
Entity Registrant Name | REGENEREX PHARMA, INC. | |
Entity Central Index Key | 0001357878 | |
Entity Tax Identification Number | 98-0479983 | |
Entity Incorporation, State or Country Code | NV | |
Entity Address, Address Line One | 5348 Vegas Drive #177 | |
Entity Address, City or Town | Las Vegas | |
Entity Address, State or Province | NV | |
Entity Address, Postal Zip Code | 89108 | |
City Area Code | (702) | |
Local Phone Number | 273-3772 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | true | |
Elected Not To Use the Extended Transition Period | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 277,112,660 | |
Entity Information, Former Legal or Registered Name | Peptide Technologies, Inc. |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Dec. 31, 2021 | Mar. 31, 2021 |
Current Assets | ||
Cash and equivalents | $ 2,789 | $ 6,902 |
Prepaid expenses | 1,213 | |
Total Current Assets | 2,789 | 8,115 |
Website, net of accumulated amortization of $21,974 and $19,645, respectively | 8,626 | 2,355 |
Total Assets | 11,415 | 10,470 |
Current Liabilities | ||
Accounts payable | 47,813 | 48,038 |
Related party advances | 131,447 | 130,992 |
Accrued compensation | 221,192 | 221,192 |
Other accrued liabilities | 79,524 | 71,003 |
Current portion of notes payable to shareholder | 118,853 | 150,094 |
Total Current Liabilities | 598,829 | 621,319 |
Notes payable to shareholder, net of current portion | 349,754 | 224,177 |
Total Liabilities | 948,583 | 845,496 |
Common stock: $0.001 par value: 675,000,000 shares authorized: 277,112,660 and 127,112,660 issued and outstanding at December 31, 2021 and March 31, 2021, respectively | 277,113 | 127,113 |
Additional paid-in capital | 671,963 | 776,963 |
Accumulated deficit | (1,886,244) | (1,739,102) |
Total Stockholders’ Deficit | (937,168) | (835,026) |
Total Liabilities and Stockholders’ Deficit | $ 11,415 | $ 10,470 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - USD ($) | Dec. 31, 2021 | Mar. 31, 2021 |
Statement of Financial Position [Abstract] | ||
Accumulated Amortization, Website | $ 21,974 | $ 19,645 |
Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 675,000,000 | 675,000,000 |
Common Stock, Shares, Issued | 277,112,660 | 127,112,660 |
Common Stock, Shares, Outstanding | 277,112,660 | 127,112,660 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | ||||
Sales | $ 181 | $ 378 | ||
Cost of Sales | 364 | 406 | ||
Gross Loss | (183) | (28) | ||
Operating Expenses | ||||
General and administrative | 62,385 | 12,103 | 100,192 | 33,229 |
Sales and marketing | 612 | 1,966 | 3,303 | 3,056 |
Total Operating Expenses | 62,997 | 14,069 | 103,495 | 36,285 |
Operating Loss | (62,997) | (14,252) | (103,495) | (36,313) |
Other Income (Expense) | ||||
Interest expense | (14,548) | (11,203) | (44,130) | (31,335) |
Foreign currency gain (loss) | (1,889) | (8,228) | 483 | (1,624) |
Total Other Income (Expense) | (16,437) | (19,431) | (43,647) | (32,959) |
Net Loss | $ (79,434) | $ (33,683) | $ (147,142) | $ (69,272) |
Basic and Diluted Loss per Common Share | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted Average Number of Common Shares Outstanding | 203,743,095 | 127,112,660 | 152,749,024 | 127,112,660 |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) | 9 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Cash Flows from Operating Activities: | ||
Net loss | $ (147,142) | $ (69,272) |
Adjustments to reconcile net loss to cash flows used in operating activities: | ||
Depreciation | 2,329 | 4,167 |
Foreign currency adjustments | (483) | 1,624 |
Stock-based compensation | 45,000 | |
Changes in operating assets and liabilities: | ||
Inventories | 406 | |
Prepaid expenses | 1,213 | (1,645) |
Accounts payable and accrued liabilities | 36,033 | 27,168 |
Net cash used in operating activities | (63,050) | (37,552) |
Cash Flows from Investing Activities: | ||
Website | (8,600) | |
Net cash used in investing activities | (8,600) | |
Cash Flows from Financing Activities: | ||
Related party advances | 455 | |
Proceeds from notes payable to shareholder | 67,082 | 33,813 |
Net cash provided by financing activities | 67,537 | 33,813 |
Decrease in cash and equivalents | (4,113) | (3,739) |
Cash and cash equivalents, beginning of period | 6,902 | 5,460 |
Cash and cash equivalents, end of period | 2,789 | 1,721 |
Income Taxes | ||
Interest | ||
Non-Cash Investing and Financing Activities: | ||
Accrued interest converted into note payable to shareholder | $ 27,254 |
STATEMENTS OF STOCKHOLDERS' DIF
STATEMENTS OF STOCKHOLDERS' DIFICIT - USD ($) | 3 Months Ended | 6 Months Ended | 9 Months Ended | |||
Dec. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2021 | Sep. 30, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Balance at September 30, 2021 | $ (902,734) | $ (516,863) | $ (835,026) | $ (481,274) | $ (835,026) | $ (481,274) |
Common Stock, Shares, Outstanding, Beginning Balance | 127,112,660 | 127,112,660 | ||||
Net Loss | (79,434) | (33,683) | $ (67,708) | (35,589) | $ (147,142) | (69,272) |
Balance at December 31, 2021 | $ (937,168) | (550,546) | (902,734) | (516,863) | $ (937,168) | (550,546) |
Common Stock, Shares, Outstanding, Ending Balance | 277,112,660 | 277,112,660 | ||||
Common stock issued for purchase of intellectual property | ||||||
Stock-based compensation | 45,000 | |||||
Common Stock [Member] | ||||||
Balance at September 30, 2021 | $ 127,113 | $ 127,113 | $ 127,113 | $ 127,113 | $ 127,113 | $ 127,113 |
Common Stock, Shares, Outstanding, Beginning Balance | 127,112,660 | 127,112,660 | 127,112,660 | 127,112,660 | 127,112,660 | 127,112,660 |
Net Loss | ||||||
Balance at December 31, 2021 | $ 277,113 | $ 127,113 | $ 127,113 | $ 127,113 | $ 277,113 | $ 127,113 |
Common Stock, Shares, Outstanding, Ending Balance | 277,112,660 | 127,112,660 | 127,112,660 | 127,112,660 | 277,112,660 | 127,112,660 |
Common stock issued for purchase of intellectual property | 150,000 | |||||
Common stock issued for purchase of intellectual property | 150,000,000 | |||||
Stock-based compensation | ||||||
Additional Paid-in Capital [Member] | ||||||
Balance at September 30, 2021 | $ 776,963 | $ 776,963 | $ 776,963 | $ 776,963 | $ 776,963 | $ 776,963 |
Net Loss | ||||||
Balance at December 31, 2021 | $ 671,963 | 776,963 | 776,963 | 776,963 | 671,963 | 776,963 |
Common stock issued for purchase of intellectual property | (150,000) | |||||
Stock-based compensation | 45,000 | |||||
Retained Earnings [Member] | ||||||
Balance at September 30, 2021 | $ (1,806,810) | (1,420,939) | (1,739,102) | (1,385,350) | (1,739,102) | (1,385,350) |
Net Loss | (79,434) | (33,683) | (67,708) | (35,589) | ||
Balance at December 31, 2021 | $ (1,886,244) | $ (1,454,622) | $ (1,806,810) | $ (1,420,939) | $ (1,886,244) | $ (1,454,622) |
Common stock issued for purchase of intellectual property | ||||||
Stock-based compensation |
NATURE OF OPERATIONS
NATURE OF OPERATIONS | 9 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
NATURE OF OPERATIONS | NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the “Company” or “Regenerex”), was incorporated in the State of Nevada, United States of America, on . The Company’s business was to develop and market proprietary skincare products that was to be sold online. The majority of manufacturing, distribution, marketing, and sales operations was outsourced. The Company’s attempt over the past four years to build a business that marketed skincare products online has not come to fruition, so management decided to change the business focus and look for other opportunities. On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th Management has decided to focus on this new business development. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company’s investors. |
BASIS OF PRESENTATION OF INTERI
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS | NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States of America. The accompanying interim unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the year ending March 31, 2022. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended March 31, 2021 have been omitted. This report should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2021 included within the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. |
GOING CONCERN
GOING CONCERN | 9 Months Ended |
Dec. 31, 2021 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
GOING CONCERN | NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2021, it had excess liabilities over assets of $937,168 These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “ Earnings per Share December 31 , 2021 and 2020, the Company does not have any common share equivalents outstanding. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $ and $ and $ and $ , respectively. Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 9 Months Ended |
Dec. 31, 2021 | |
Related Party Transactions [Abstract] | |
RELATED PARTY TRANSACTIONS | NOTE 5 – RELATED PARTY TRANSACTIONS The Company purchased assets from the Company’s current Chief Executive Officer (“CEO”) and Secretary/Treasurer (see note 6). Related Party Advances The Company’s former Chief Financial Officer (“CFO”) has historically advanced the Company monies for operating expenses; Advances during the nine-month period December 31, 2021 and 2020 were $455 and $0, respectively. The related party advances totaled $ and $ as of December 31, 2021 and March 31, 2021, respectively. The advances are due on demand. The related party advances accrue interest at ten (10) percent per annum. Repayment is due no later than June 30, 2023. Interest expense was $ and $ during the nine-month periods ended December 31, 2021 and 2020, respectively. Note Payables to Shareholders As at December 31, 2021 and March 31, 2021, the Company had various promissory notes with total outstanding principal balances of $468,607 and $374,271, respectively, due to a shareholder of the Company. These notes are unsecured, bear interest at 10% per annum, and have maturity dates ranging from January 20, 2022 to December 30, 2023. On April 15, 2021, one note to a shareholder that was originally due on April 15, 2021 with a principal amount of approximately $72,000 ($90,000 Canadian Funds) was reissued in the principal amount of approximately $86,000 ($108,000 Canadian Funds) which included the original principal amount plus interest accrued as at April 15, 2021 in the amount of approximately $14,000 ($18,000 Canadian Funds). Repayment of the note is due no later than April 15, 2023. On October 11, 2021 one note to a shareholder that was originally due on October 11, 2021 with a principal amount of $10,000 was reissued in the principal amount of $12,000 which included the original principal plus interest accrued as at October 11, 2021 in the amount of $2,000. Repayment of the note is due no later than October 11, 2023. On October 21, 2021, one note to a shareholder that was originally due on October 21, 2021 with a principal amount of $30,000 was reissued in the principal amount of $36,000 which included the original principal plus interest accrued as at October 21, 2021 in the amount of $6,000. Repayment of the note is due no later than October 21, 2023. On October 25, 2021, one note to a shareholder that was originally due on October 25, 2021 with a principal amount of $24,500 was reissued in the principal amount of $29,400 which included the original principal plus interest accrued as at October 25, 2021 in the amount of $4,900. Repayment of the note is due no later than October 25, 2023. On December 9, 2021, one note to a shareholder that was originally due on December 9, 2021 with a principal amount of approximately $4,000 ($5,000 Canadian Funds) was reissued in the principal amount of approximately $5,000 ($6,000 Canadian Funds) which included the original principal plus interest accrued as at December 9, 2021 in the amount of approximately $758 ($1,000 Canadian Funds). Repayment of the note is due no later than December 9, 2023. During the nine-month period ended December 31, 2021, a shareholder was issued additional eight (8) promissory notes totaling $67,082 ($86,500 Canadian Funds). These notes are unsecured and bear interest at ten (10) percent per annum with principal and interest due twenty-four (24) months after the date of issue. Accrued interest was $42,676 and $33,132 as of December 31, 2021 and March 31, 2021, respectively, which is included in other accrued liabilities. |
INTANGIBLE ASSETS AND INTELLECT
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY | 9 Months Ended |
Dec. 31, 2021 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY | NOTE 6 – INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company’s common stock and up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months. The Company will receive all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter and capture a high proportionate market share in the U.S. The Technology Platforms include but are not limited to: A. Proteomic research platforms which include proprietary blends. B. Combination design Techniques C. Patent Pending Proprietary Blends D. Patent Pending Formulas E. Trademarks and all pending Trademarks F. 510K USA FDA, information and Know-how for application G. All Clinical trials, (Right to use) H. CE mark (International) I. Regenerex Library formula incorporated in the Wound Healing Technology. J. Wound Healing Technology QBX K. Synthetic Compositions of Cations derived from botanical material in the ash of Red- Oak Bark. Products: 1. Xcellderma over the counter product. 2. Accelerex, combination product as a drug device. 3. Accelerex in a tube. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 9 Months Ended |
Dec. 31, 2021 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | NOTE 7 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers. See Note 6 for discussion of the $10,000,000 in contingent consideration to be paid in connection with the November 15, 2021 Asset Purchase Agreement. To date, no amounts have been payable under this agreement. |
STOCKHOLDERS_ DEFICIT
STOCKHOLDERS’ DEFICIT | 9 Months Ended |
Dec. 31, 2021 | |
Equity [Abstract] | |
STOCKHOLDERS’ DEFICIT | NOTE 8 – STOCKHOLDERS’ DEFICIT During the three months ended December 31, 2021, Irene Getty, who resigned as a member of the Board of Directors, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Gregory Pilant and Deborah Pilant upon their appointment as Directors and Officers of the Company. Irene Getty continues to be the Chief Financial Officer of the Company. Irene Getty was a significant shareholder owning more than 10% of the shares outstanding at the time. The Company recognized stock-based compensation of $45,000 within general and administrative expenses in the accompanying statement of operations related to this transfer of shares. See Note 6 for shares issued in connection with the Asset Purchase Agreement. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Dec. 31, 2021 | |
Subsequent Events [Abstract] | |
SUBSEQUENT EVENTS | NOTE 9 – SUBSEQUENT EVENTS On January 20, 2022, a note to a shareholder that was originally due on January 20, 2022 with a principal amount of approximately $8,000 ($10,000 Canadian Funds) was reissued in the principal amount of approximately $10,000 ($12,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 20, 2022 in the approximate amount of $2,000 ($2,000 Canadian Funds). Repayment of the note is due no later than January 20, 2024. On January 31, 2022, a note to a shareholder that was originally due on January 31, 2022 with a principal amount of approximately $53,000 ($70,000 Canadian Funds) was reissued in the principal amount of approximately $66,000 ($84,000 Canadian Funds), which included the original principal amount plus interest accrued as at January 31, 2022 in the approximate amount of $11,000 ($14,000 Canadian Funds). Repayment of the note is due no later than January 31, 2024. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 9 Months Ended |
Dec. 31, 2021 | |
Accounting Policies [Abstract] | |
Revenue Recognition | Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government. The Company defers revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. |
Earnings per Share | Earnings per Share Earnings per share is reported in accordance with FASB Accounting Standards Codification (“ASC”) Topic 260 “ Earnings per Share December 31 , 2021 and 2020, the Company does not have any common share equivalents outstanding. |
Website | Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the three and nine months ended December 31, 2021 and 2020 was $ and $ and $ and $ , respectively. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Financial Accounting Standards Board issued Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. |
NATURE OF OPERATIONS (Details N
NATURE OF OPERATIONS (Details Narrative) - USD ($) | 9 Months Ended | |
Dec. 31, 2021 | Nov. 15, 2021 | |
Entity Incorporation, Date of Incorporation | Nov. 18, 2005 | |
Asset Acquisition, Contingent Consideration, Liability | $ 10,000,000 | |
Purchase Intellectual Property [Member] | ||
Shares, Issued | 150,000,000 |
GOING CONCERN (Details Narrativ
GOING CONCERN (Details Narrative) - USD ($) | Dec. 31, 2021 | Sep. 30, 2021 | Mar. 31, 2021 | Dec. 31, 2020 | Sep. 30, 2020 | Mar. 31, 2020 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||
Stockholders' Equity Attributable to Parent | $ 937,168 | $ 902,734 | $ 835,026 | $ 550,546 | $ 516,863 | $ 481,274 |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | |
Accounting Policies [Abstract] | ||||
Amortization of Intangible Assets | $ 1,016 | $ 2,329 | $ 504 | $ 4,167 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 31, 2021 | |
Related Party Transaction [Line Items] | |||||
Related Party Advances | $ 131,447 | $ 131,447 | $ 131,447 | $ 130,992 | |
Interest Expense, Related Party | 9,879 | $ 9,869 | |||
Debt Instrument, Maturity Date Range, Start | Jan. 20, 2022 | ||||
Debt Instrument, Maturity Date Range, End | Dec. 30, 2023 | ||||
Notes Payable | $ 349,754 | $ 349,754 | 349,754 | 224,177 | |
Debt Instrument, Maturity Date, Description | due twenty-four (24) months after the date of issue | ||||
Accrued Interest | $ 42,676 | 42,676 | 42,676 | 33,132 | |
April 15 Note 2021 [Member] | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Face Amount | $ 86,000 | 86,000 | 86,000 | ||
Debt Instrument, Maturity Date | Apr. 15, 2023 | ||||
October 11 Note 2021 [Member] | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Face Amount | $ 12,000 | 12,000 | 12,000 | ||
Debt Instrument, Maturity Date | Oct. 11, 2023 | ||||
October 21 Note 2021 [Member] | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Face Amount | $ 36,000 | 36,000 | 36,000 | ||
Debt Instrument, Maturity Date | Oct. 21, 2023 | ||||
October 25 Note 2021 [Member] | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Face Amount | $ 29,400 | 29,400 | 29,400 | ||
Debt Instrument, Maturity Date | Oct. 25, 2023 | ||||
December 9 Note 2021 [Member] | |||||
Related Party Transaction [Line Items] | |||||
Debt Instrument, Face Amount | $ 5,000 | 5,000 | 5,000 | ||
Debt Instrument, Maturity Date | Dec. 9, 2023 | ||||
Chief Executive Officer [Member] | |||||
Related Party Transaction [Line Items] | |||||
Related Party Advances | $ 455 | 455 | 455 | $ 0 | |
Note Payable To Shareholder [Member] | |||||
Related Party Transaction [Line Items] | |||||
Long-term Debt, Fair Value | $ 468,607 | $ 468,607 | $ 468,607 | $ 374,271 | |
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | 10.00% | 10.00% | 10.00% | |
Notes Payable | $ 67,082 | $ 67,082 | $ 67,082 |
INTANGIBLE ASSETS AND INTELLE_2
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY (Details Narrative) | 1 Months Ended |
Nov. 15, 2021shares | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 150,000,000 |
Business Combination, Contingent Consideration Arrangements, Description | up to $10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15th of the following month, for a period of 60 months |
STOCKHOLDERS_ DEFICIT (Details
STOCKHOLDERS’ DEFICIT (Details Narrative) - USD ($) | 9 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Equity [Abstract] | ||
Share-based Payment Arrangement, Noncash Expense | $ 45,000 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | 1 Months Ended | |
Jan. 31, 2022 | Jan. 20, 2022 | |
Promissory Note 1 [Member] | ||
Short-term Debt [Line Items] | ||
Debt Instrument, Issuance Date | Jan. 20, 2022 | |
Debt Instrument, Face Amount | $ 10,000 | |
Debt Instrument, Maturity Date | Jan. 20, 2024 | |
Promissory Note 2 [Member] | ||
Short-term Debt [Line Items] | ||
Debt Instrument, Issuance Date | Jan. 31, 2022 | |
Debt Instrument, Face Amount | $ 66,000 | |
Debt Instrument, Maturity Date | Jan. 31, 2024 |